Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company

Alternative Names: BI-10773; Jardiance; Oboravo

Latest Information Update: 01 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Duke Clinical Research Institute; Eli Lilly and Company; Kobe University; Medical University of Vienna; Mount Sinai Hospital (Toronto); University of Oxford; Yale University
  • Class Antihyperglycaemics; Benzhydryl compounds; Cardiovascular therapies; Chlorinated hydrocarbons; Cyclic ethers; Glucosides; Heart failure therapies; Small molecules; Urologics
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Chronic heart failure; Renal failure; Type 2 diabetes mellitus
  • Phase III Acute heart failure; Gestational diabetes; Heart failure; Insulin resistance; Type 1 diabetes mellitus
  • Phase II Decompensated heart failure; Kidney disorders

Most Recent Events

  • 02 Jul 2024 Boehringer Ingelheim completes the phase III EMPA-KIDNEY trial in Renal failure in USA, Canada, China, Germany, Italy, Malaysia, Japan, United Kingdom (PO) (NCT03594110)
  • 06 Apr 2024 Adverse events and efficacy data from the phase-III EMPACT-MI trial in Acute heart failure released by Eli Lilly and Company
  • 23 Jan 2024 Registered for Renal failure in Canada (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top